Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Ashley K Elrod"'
Autor:
Teresa M DesRochers, Danielle Nadeau, Katy A Lassahn, Ashley K Elrod, Natalie W Dance, Kimberly J Burgess, Aaron L Carlson, Melissa Millard, Michael J Wick, Kathryn M Appleton
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/766d95c0b234474891756f460d0c7398
Autor:
Katy A. Lassahn, Ashley K. Elrod, Aaron L. Carlson, Natalie A. Dance, Melissa Millard, Michael J. Wick, Teresa M. DesRochers, Kathryn M. Appleton
Publikováno v:
Cancer Research. 83:2275-2275
Biological therapies for the treatment of cancer are utilized for the same ultimate purpose as chemically derived cancer drugs, to induce tumor cell death. However, the differing mechanisms of action often make the evaluation of biologic drug efficac
Publikováno v:
Cancer Research. 82:287-287
Cancer treatment has evolved with the advent of immunotherapies. This drug class now plays a key role in supplementing or even replacing chemotherapies as first line treatments. Immunotherapies such as immune checkpoint inhibitors, bispecific antibod
Autor:
Melissa Rayner, Katherine Miles, Kimberly Burgess, Taylor Brooks, Ashley K. Elrod, Natalie A. Williams, Jeremy Stuart, Lillia Holmes, Teresa M. DesRochers
Publikováno v:
Cancer Research. 82:2773-2773
Treatment paradigms for cancer patients have evolved as technology has advanced. Initial treatment guidelines were developed from probability-based assessments of the likelihood of groups of patients to respond to a compound. Biomarkers such as HER2
Publikováno v:
Cancer Research. 82:4162-4162
Agents that invoke an immune response against tumors, such as immune checkpoint inhibitors (ICIs), have revolutionized cancer treatment. Understanding the efficacy of these agents involves more than just the characterization of patient-specific tumor
Autor:
Aaron L. Carlson, Ashley K. Elrod, Natalie A. Williams, Alyssa D. Moriarty, Michael J. Wick, Teresa M. DesRochers
Publikováno v:
Cancer Research. 82:183-183
Patient-Derived Xenografts (PDX) represent a versatile tool for preclinical drug development because they recapitulate many key features of the parent tumors, including molecular and histopathological profiles, tumor microenvironment, and tumor heter
Publikováno v:
Cancer Research. 82:3086-3086
Unlike cell lines, organoids maintain most of the biological properties of the parental tissue from which the starting cells were isolated including the histology and gene expression. When organoids include clinical annotation, they become a useful,